Alpha Tau Announces Appointment of Maya Netser to its Board of Directors; Board Member Meir Jakobsohn Stepping Down, Staying on as Advisor
17 Décembre 2024 - 3:00PM
Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW), ("Alpha Tau" or the
"Company"), the developer of the innovative alpha-radiation cancer
therapy Alpha DaRT®, announced today that following its Annual
General Meeting of Company shareholders in Jerusalem, Ms. Maya
Netser has been appointed to the Company’s Board of Directors
(“Board”). Mr. Meir Jakobsohn is completing his term on the Board,
having decided not to pursue re-election, but will continue to
serve the Company in an advisory capacity.
“I am delighted to welcome Maya to the Board,”
said Company CEO and Chairman of the Board Mr. Uzi Sofer. “Maya
brings a wealth of experience and a keen understanding of the
industry from her many years of corporate leadership and advisory.
She joins us as the Company is at an exciting strategic inflection
point, undertaking a highly promising expansion into the treatment
of internal organs. I am sure that Maya will be a wonderful partner
in our mission to raise the standard of care for cancer patients
worldwide.”
“I am so pleased to join Alpha Tau’s Board of
Directors,” commented Ms. Netser. “I have been following the
Company’s achievements with great interest and am eager to bring my
life sciences and business development skills to help the Company
continue to meet its extraordinary potential.”
Ms. Netser has over 25 years of experience as a
C-level technology company leader, board member, investor, advisor,
and law firm partner. Ms. Netser is the founder and Managing
Partner of Quantum Leap VC, an early-stage fund focused on quantum
technologies. Previously, Ms. Netser served as CEO of Cabaret
Biotech, an Israeli CAR-T immunotherapy company based on Professor
Zelig Eshhar’s pioneering inventions in cancer immunotherapy. Under
her leadership, Cabaret successfully commercialized its IP,
culminating in a high-profile acquisition by Kite Pharma and Gilead
Sciences.
She previously served as COO and board member of
Voyager Labs, an AI-based technology company that enables
organizations to extract granular actionable insights from
unstructured data. She was responsible for corporate business
development, finance, human resources, legal, and investor
relations.
Ms. Netser also has over 20 years of corporate
and IP legal experience. From 2006-2015, she was a Partner at the
law firm Herzog, Fox, and Neeman, where she established and led the
firm’s technology practice, growing her team to 30 lawyers.
Ms. Netser holds an LL.B and an MBA from Tel
Aviv University. She is also a member of the Israeli National Team
of Directors.
In addition, the Company announced that Mr. Meir
Jakobsohn has completed his term as a Board member but will
continue to serve an advisory role to the Company.
“Meir has been a long-standing and deeply valued
Board member who has contributed greatly to Alpha Tau’s success,”
said Mr. Sofer. “I thank him for his many years of excellent
service and I look forward to continuing to receive his wise
counsel as a Company advisor.”
“Due to other commitments, I have decided not to
seek re-election as a member of Alpha Tau’s Board,” Mr. Jakobsohn
remarked. “It has been a privilege to have been a part of the
Company’s extremely impressive growth from a small start-up to a
public company with a highly advanced and sophisticated strategic
pipeline. I wish Uzi and the Company the best of luck, and I am
pleased to be able to stay connected with the Company as an
advisor.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli
oncology therapeutics company that focuses on research,
development, and potential commercialization of the Alpha DaRT for
the treatment of solid tumors. The technology was initially
developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel
Aviv University.
About Alpha DaRT ®
Alpha DaRT (Diffusing Alpha-emitters Radiation
Therapy) is designed to enable highly potent and conformal
alpha-irradiation of solid tumors by intratumoral delivery of
radium-224 impregnated sources. When the radium decays, its
short-lived daughters are released from the sources and disperse
while emitting high-energy alpha particles with the goal of
destroying the tumor. Since the alpha-emitting atoms diffuse only a
short distance, Alpha DaRT aims to mainly affect the tumor, and to
spare the healthy tissue around it.
Forward-Looking Statements
This press release includes "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. When used herein, words including "anticipate,"
"being," "will," "plan," "may," "continue," and similar expressions
are intended to identify forward-looking statements. In addition,
any statements or information that refer to expectations, beliefs,
plans, projections, objectives, performance or other
characterizations of future events or circumstances, including any
underlying assumptions, are forward-looking. All forward-looking
statements are based upon Alpha Tau's current expectations and
various assumptions. Alpha Tau believes there is a reasonable basis
for its expectations and beliefs, but they are inherently
uncertain. Alpha Tau may not realize its expectations, and its
beliefs may not prove correct. Actual results could differ
materially from those described or implied by such forward-looking
statements as a result of various important factors, including,
without limitation: (i) Alpha Tau's ability to receive regulatory
approval for its Alpha DaRT technology or any future products or
product candidates; (ii) Alpha Tau's limited operating history;
(iii) Alpha Tau's incurrence of significant losses to date; (iv)
Alpha Tau's need for additional funding and ability to raise
capital when needed; (v) Alpha Tau's limited experience in medical
device discovery and development; (vi) Alpha Tau's dependence on
the success and commercialization of the Alpha DaRT technology;
(vii) the failure of preliminary data from Alpha Tau's clinical
studies to predict final study results; (viii) failure of Alpha
Tau's early clinical studies or preclinical studies to predict
future clinical studies; (ix) Alpha Tau's ability to enroll
patients in its clinical trials; (x) undesirable side effects
caused by Alpha Tau's Alpha DaRT technology or any future products
or product candidates; (xi) Alpha Tau's exposure to patent
infringement lawsuits; (xii) Alpha Tau's ability to comply with the
extensive regulations applicable to it; (xiii) the ability to meet
Nasdaq's listing standards; (xiv) costs related to being a public
company; (xv) changes in applicable laws or regulations; and the
other important factors discussed under the caption "Risk Factors"
in Alpha Tau's annual report filed on form 20-F with the SEC on
March 7, 2024, and other filings that Alpha Tau may make with the
United States Securities and Exchange Commission. These and other
important factors could cause actual results to differ materially
from those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent
management's estimates as of the date of this press release. While
Alpha Tau may elect to update such forward-looking statements at
some point in the future, except as required by law, it disclaims
any obligation to do so, even if subsequent events cause its views
to change. These forward-looking statements should not be relied
upon as representing Alpha Tau's views as of any date subsequent to
the date of this press release.
Investor Relations Contact:
IR@alphatau.com
Alpha Tau Medical (NASDAQ:DRTS)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Alpha Tau Medical (NASDAQ:DRTS)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024